Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B surface antigen + adjuvant 3
- Development stage
- Unknown
- Lead developer
- VBI Vaccines
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
hepatitis B surface antigen + adjuvant 3 is a combination vaccine formulation intended to induce immunity against hepatitis B virus (HBV) infection. The active ingredient, hepatitis B surface antigen (HBsAg), is typically produced recombinantly and may include multiple envelope proteins (S, M, L) that form virus-like particles. The addition of "adjuvant 3" refers to the inclusion of a third-generation or novel adjuvant designed to enhance the magnitude and quality of the immune response, improve seroprotection rates, and potentially allow for a lower antigen dose. Adjuvants used in advanced HBV vaccine formulations may include synthetic molecules (such as L-pampo, a lipopeptide/dsRNA coprecipitate[2]) or newly developed polymers (such as PEG–PAEEP[4]), which aim to stimulate a robust Th1-type response and increase IgG titers. This combination is typically indicated for primary prevention of hepatitis B infection across various age groups, including neonates, children, and adults at risk[1][2][4].
- Other names
- hepatitis B surface antigen + adjuvant 3
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B surface antigen + adjuvant 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B surface antigen + adjuvant 3.